Surgery Partners Inc SEC Filings

Surgery Partners, Inc. reported an equity award for executive Justin Robert Oppenheimer, who serves as COO & National Group President. On January 13, 2026, he received 77,736 shares of common stock as a restricted stock award at a reference price of $16.08 per share. These restricted stock awards vest in a single installment on the first anniversary of the grant date, meaning all shares are scheduled to vest together after one year.

Following this grant, Oppenheimer is shown as beneficially owning 77,736 shares of Surgery Partners common stock with direct ownership. The filing reflects a compensation-related equity grant rather than an open-market purchase or sale.

Surgery Partners, Inc. executive Justin Robert Oppenheimer, who serves as COO & National Group President, filed an initial ownership report on Form 3. The filing states that he beneficially owns 0 shares of Common Stock on a direct basis as of 01/01/2026. The derivative securities table shows no stock options, warrants, or other derivative securities reported as beneficially owned. The form is signed by an attorney-in-fact under a power of attorney, indicating this is a baseline disclosure of his current equity holdings with the company.

Surgery Partners, Inc., through its wholly-owned subsidiary Surgery Center Holdings, Inc., issued an additional $425.0 million aggregate principal amount of 7.250% Senior Notes due 2032. The new notes were issued under a Third Supplemental Indenture dated December 16, 2025, with Wilmington Trust, National Association as trustee.

The additional notes have the same terms as the existing $800.0 million 7.250% Senior Notes due 2032 and will be treated as a single series with those notes under the same CUSIP number. Any notes issued pursuant to Regulation S will trade separately under a different CUSIP number until 40 days after the issue date before becoming fungible for U.S. federal income tax purposes with the existing and other new notes.

Surgery Partners, Inc., through its subsidiary Surgery Center Holdings, Inc., agreed to issue and sell $425.0 million in aggregate principal amount of 7.250% senior unsecured notes due 2032. These notes are being sold under a purchase agreement with Barclays Capital Inc., acting as representative of the initial purchasers. The company plans to use the net proceeds for general corporate purposes, including repaying outstanding borrowings under its revolving credit facility. The completion of this notes offering is described as being subject to market and other conditions, meaning it is not yet finalized. Surgery Partners also announced the pricing of the notes in a press release dated December 11, 2025.

Surgery Partners, Inc. reported that its wholly owned subsidiary, Surgery Center Holdings, Inc., intends to offer $425.0 million of additional 7.250% Senior Notes due 2032. The notes are expected to be offered in a private transaction conducted under Rule 144A and Regulation S.

The company stated that net proceeds are expected to be used for general corporate purposes, which may include repaying outstanding borrowings under its revolving credit facility. Surgery Partners also cautioned that the offering may not be completed on the terms or in the amounts anticipated, or at all, and referenced existing risk factors in its annual and quarterly reports.

Surgery Partners, Inc. announced the appointment of Justin Oppenheimer as Chief Operating Officer and National Group President, effective January 1, 2026. He joins from the Hospital for Special Surgery, where he spent a decade in leadership roles including Chief Strategy Officer and Chief Operating Officer.

Oppenheimer serves on the board of Urban Dove, a New York-based charter school management organization, and holds a B.A. in political economy from Princeton University and an MBA from Harvard Business School. The company referenced his employment agreement as Exhibit 10.1, dated October 27, 2025.

Surgery Partners, Inc. (SGRY) reported higher revenue and improved operating performance in Q3 2025. Revenue rose to $821.5 million from $770.4 million, driven by same‑facility growth and recent portfolio actions. Operating income increased to $105.7 million from $60.9 million as salaries, supplies, and professional fees scaled with volume. Net loss attributable to Surgery Partners narrowed to $22.7 million from $31.7 million as interest expense remained elevated at $74.9 million.

Management highlighted days‑adjusted same‑facility revenue up 6.3% year over year, with a 2.8% increase in revenue per case and a 3.4% lift in same‑facility cases. For the nine months, revenue reached $2,423.7 million versus $2,249.9 million, while the net loss attributable to the company was $62.9 million.

Liquidity and capital structure shifted following an August refinancing. The company entered into $1,383 million of 2025 Refinancing Term Loans maturing in 2030 at Term SOFR plus 2.50% (or an alternate base rate plus 1.50%) and extended revolving commitments to 2028. Cash and cash equivalents were $203.4 million, with $405.9 million of availability on the $703.8 million revolver. Total debt was $3,563.6 million, including $800.0 million of 7.250% senior notes due 2032. As of November 3, 2025, common shares outstanding were 129,341,779.

Surgery Partners, Inc. (SGRY) furnished an 8-K announcing results for the three and nine months ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing the period’s performance.

The disclosure under Item 2.02 is provided pursuant to General Instruction B.2 and is deemed furnished, not filed. The release includes non-GAAP financial measures with reconciliations to the most comparable GAAP measures.

Surgery Partners, Inc. (SGRY) submitted a Form 144 notifying a proposed sale of 3,145 common shares through UBS Financial Services with an approximate market value of 65,269.9, and an approximate sale date of 10/09/2025 on NASDAQ. The securities were acquired on 10/09/2025 via equity compensation and paid by equity option exercise.

The filing also lists multiple prior open-market sales by the named person, Wayne DeVeydt, across dates from 08/21/2025 to 10/08/2025, including several large single-day blocks (up to 150,000 shares). The notice includes the required attestation that the seller is not aware of undisclosed material adverse information.